Business
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million. This action underscores their strong confidence in the Company's long-term growth prospects.
About this update from Jacobio Pharmaceuticals Group Co., Ltd.
[{"type":"text","content":"BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million. This action underscores their strong confidence in the Company's long-term growth prospects.","length":456,"tagName":"p"},{"type":"text","content":"In addition, the Company's share repurchase plan with an upper limit of HK$100 million, which was approved by the Board in July 2025, has already led to the repurchase of 326,400 shares, with a cumulative payment of HK$2.67 million. The Company will continue to implement the repurchase plan based on market conditions.","length":323,"tagName":"p"},{"type":"text","content":"In the interim results for 2025 released earlier, Jacobio reported multiple encouraging R&D achievements. The Company continues to focus on two major R&D pillars – KRAS and iADC – with core programs making steady progress, further demonstrating Jacobio's competitiveness and growth potential in the global biopharmaceutical sector.","length":343,"tagName":"p"},{"type":"text","content":"Within the KRAS pathway, Jacobio has established a comprehensive development strategy. In May 2025, the Company's KRAS G12C inhibitor, Glecirasib, was approved by the National Medical Products Administration (NMPA) for second-line monotherapy in KRAS G12C mutant non-small cell lung cancer (NSCLC) and successfully launched in China. This milestone not only marked Jacobio's first commercial entry into the Chinese market but also triggered a milestone payment of RMB 50 million from its partner Allist. At the same time, Glecirasib is being evaluated in combination with the SHP2 inhibitor sitneprotafib for first-line NSCLC.","length":634,"tagName":"p"},{"type":"text","content":"Beyond its marketed product, Jacobio's pan-KRAS inhibitor JAB-23E73 has shown important progress. In the dose-escalation phase of its Phase I clinical trial, multiple confirmed partial responses (PRs) have been observed, with favorable safety and pharmacokinetic (PK) profiles consistent with expectations. Full Phase I data are expected to be released in the first half of 2026, which ...